{"id":2934,"date":"2017-08-12T11:12:57","date_gmt":"2017-08-12T11:12:57","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/?p=2934"},"modified":"2026-01-05T11:55:24","modified_gmt":"2026-01-05T11:55:24","slug":"studiu-clinic-hipertermie-profunda","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/ro\/studiu-clinic-hipertermie-profunda\/","title":{"rendered":"Studiu de cvasi fezabilitate (caz de control) care asociaz\u0103 tratamentul hipertermiei locale profunde cu tratamente standard pentru cancer \u0219i descrie modelele de r\u0103spuns ESHO"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/studiu-clinic-hipertermie-profunda\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/studiu-clinic-hipertermie-profunda\/\",\n      \"name\": \"Studiu Clinic HyDeep 600WM: Fezabilitatea \u00een Oncologia Public\u0103 | Andromedic\",\n      \"description\": \"Dovezi clinice din spitalele publice din Spania care demonstreaz\u0103 fezabilitatea \u0219i siguran\u021ba dispozitivului Andromedic HyDeep 600WM \u00een combina\u021bie cu radioterapia \u0219i chimioterapia.\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"inLanguage\": \"ro\",\n      \"about\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" }\n      ]\n    },\n    {\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/studiu-clinic-hipertermie-profunda\/#article\",\n      \"headline\": \"Studiu clinic de cvasi-fezabilitate care asociaz\u0103 tratamentul de hipertermie profund\u0103 local\u0103 HyDeep 600WM cu tratamentele oncologice standard\",\n      \"author\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\" }\n      ],\n      \"publisher\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"datePublished\": \"2014-05-01\",\n      \"keywords\": [\"HyDeep 600WM\", \"Andromedic\", \"ESHO 2014\", \"Studiu Clinic Spania\", \"Hipertermie Radiofrecventa\"],\n      \"abstract\": \"Analiza a 293 de pacien\u021bi utiliz\u00e2nd dispozitivul Andromedic HyDeep 600WM. Studiul demonstreaz\u0103 capacitatea dispozitivului de a fi integrat \u00een protocoalele oncologice standard, cu o toleran\u021b\u0103 ridicat\u0103 a pacien\u021bilor (81.2%).\",\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n        { \"@type\": \"Organization\", \"name\": \"ESHO - European Society for Hyperthermic Oncology\" }\n      ]\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#esho-trial-spain-ro\",\n      \"name\": \"Validarea Clinic\u0103 a HyDeep 600WM \u00een Spitalele Publice din Andaluzia\",\n      \"studySubject\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n      \"studyLocation\": { \"@type\": \"AdministrativeArea\", \"name\": \"Andaluzia, Spania\" },\n      \"description\": \"Studiu prospectiv utiliz\u00e2nd HyDeep 600WM cu puteri \u00eentre 150W \u0219i 400W pentru tratarea a 9 localiz\u0103ri tumorale diferite.\",\n      \"healthCondition\": [\n        { \"@type\": \"MedicalCondition\", \"name\": \"Glioblastom\" },\n        { \"@type\": \"MedicalCondition\", \"name\": \"Cancer Cap \u0219i G\u00e2t\" },\n        { \"@type\": \"MedicalCondition\", \"name\": \"Cancer Mamar Avansat\" },\n        { \"@type\": \"MedicalCondition\", \"name\": \"Cancer Bronhopulmonar (NSCLC)\" },\n        { \"@type\": \"MedicalCondition\", \"name\": \"Cancer de Prostat\u0103\" }\n      ]\n    },\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"Andromedic HyDeep 600 WM\",\n      \"sku\": \"HYDEEP-600WM-ESHO-RO\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/HyDeep-600WM-Andromedic.jpg\",\n      \"description\": \"Dispozitiv profesional de hipertermie oncologic\u0103 RF utilizat \u00een studiul clinic de fezabilitate ESHO 2014 pentru hipertermie local\u0103 profund\u0103.\",\n      \"manufacturer\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.9\",\n        \"reviewCount\": \"40\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"4\"\n      },\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/contact-andromedic-romania\/\"\n      }\n    },\n    {\n      \"@type\": \"Physician\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"name\": \"Dr. Veronica Iatan\",\n      \"jobTitle\": \"Co-fondator SRHO, Expert Medical\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"address\": {\n        \"@type\": \"PostalAddress\",\n        \"streetAddress\": \"Strada Stadionului nr. 25G\",\n        \"addressLocality\": \"Clinceni\",\n        \"addressRegion\": \"Ilfov\",\n        \"postalCode\": \"077060\",\n        \"addressCountry\": \"RO\"\n      }\n    },\n    {\n      \"@type\": \"Person\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"name\": \"Cristian Gologan\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"jobTitle\": \"CEO Premium Wellness Distrib SRL, CEO & Co-fondator SRHO\"\n    }\n  ]\n}\n<\/script><\/p>\n<div style=\"line-height: 1.6; color: #333; max-width: 950px; margin: auto; font-family: 'Segoe UI', Roboto, Helvetica, Arial, sans-serif;\">\n<div style=\"background-color: #f8f9fa; padding: 40px 20px; border-radius: 15px; border-left: 5px solid #0056b3; margin-bottom: 30px; text-align: center; box-shadow: 0 4px 12px rgba(0,0,0,0.05);\">\n<h1 style=\"color: #0056b3; font-size: 26px; line-height: 1.4; margin-bottom: 20px;\"><a style=\"text-decoration: none; color: inherit;\" href=\"http:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/cartleESHOfinal.pdf\"><br \/>\nStudiu de cvasi-fezabilitate: <strong>Termoterapie Oncologic\u0103<\/strong> cu <strong>Hipertermie Local\u0103 Profund\u0103<\/strong> HyDeep 600 WM \u0219i tratamente standard cancer<br \/>\n<\/a><\/h1>\n<h2 style=\"font-size: 18px; color: #d9534f; font-weight: 600;\"><a style=\"text-decoration: none; color: inherit;\" href=\"https:\/\/www.esho.info\/\" target=\"_blank\" rel=\"noopener\"><br \/>\nPoster ESHO 2014: Validarea <strong>dispozitivului de hipertermie oncologic\u0103<\/strong> Andromedic \u00een spitalele publice<br \/>\n<\/a><\/h2>\n<\/div>\n<div style=\"max-width: 600px; margin: 0 auto 40px auto; text-align: center;\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-111 size-full\" style=\"border-radius: 8px; box-shadow: 0 4px 15px rgba(0,0,0,0.1); border: 1px solid #eee;\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg\" alt=\"Dispozitiv de hipertermie oncologic\u0103 - Studiu clinic de caz-control HyDeep 600WM\" width=\"568\" height=\"826\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg 568w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-206x300.jpg 206w\" sizes=\"auto, (max-width: 568px) 100vw, 568px\" \/><\/p>\n<p style=\"font-style: italic; color: #555; margin-top: 15px; font-size: 14px;\">Studiu de cvasi-fezabilitate (caz-control) care asociaz\u0103 tratamentul cu hipertermie local\u0103 profund\u0103 HyDeep 600WM cu tratamente standard pentru cancer \u0219i descrie modelele de r\u0103spuns<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<div style=\"margin-bottom: 35px;\">\n<h3 style=\"color: #0056b3; border-bottom: 2px solid #0056b3; display: inline-block; padding-bottom: 5px; margin-bottom: 15px;\">Introducere \u0219i Tehnologie<\/h3>\n<p style=\"font-size: 16px; background: #fff; padding: 15px; border-radius: 5px; border: 1px solid #eee;\">Acesta este primul studiu clinic care combin\u0103 <strong>hipertermia local\u0103 profund\u0103<\/strong> Andromedic HyDeep 600 WM cu tratamentele standard pentru cancer din Spania \u0219i Andaluzia. Lucrarea a fost prezentat\u0103 la congresul Societ\u0103\u021bii Europene de Hipertermie Oncologic\u0103 (<a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\">ESHO<\/a>) \u00een 2014, valid\u00e2nd metoda de <strong>electro-hipertermie RF modulat\u0103<\/strong> ca adjuvant eficient \u00een oncologie.<\/p>\n<\/div>\n<p><strong>Materiale \u0219i metode:<\/strong><\/p>\n<div style=\"display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 35px;\">\n<div style=\"background: #ffffff; border: 1px solid #e1e4e8; padding: 20px; border-radius: 12px; box-shadow: 0 2px 5px rgba(0,0,0,0.02);\">\n<h4 style=\"color: #0056b3; margin-top: 0; border-bottom: 1px solid #eee; padding-bottom: 10px;\"> Obiectivele Studiului<\/h4>\n<p><strong>Primul obiectiv:<\/strong> Analizarea beneficiilor clinice, a r\u0103spunsului la tratament, a fezabilit\u0103\u021bii tratamentului \u0219i a confortului hipertermiei oncologice combinate cu tratamentele standard pentru cancer \u00een cadrul sistemului public de s\u0103n\u0103tate.<\/p>\n<p><strong>Secundar:<\/strong> Analizarea supravie\u021buirii, a calit\u0103\u021bii vie\u021bii \u0219i a toxicit\u0103\u021bii (hipertermie general\u0103 \u0219i specific\u0103 pentru cancer \u2013 not\u0103: a nu se confunda cu afec\u021biunea rar\u0103 numit\u0103 <em>hipertermie malign\u0103<\/em>).<\/p>\n<\/div>\n<div style=\"background: #ffffff; border: 1px solid #e1e4e8; padding: 20px; border-radius: 12px; box-shadow: 0 2px 5px rgba(0,0,0,0.02);\">\n<h4 style=\"color: #0056b3; margin-top: 0; border-bottom: 1px solid #eee; padding-bottom: 10px;\"> Design &amp; E\u0219antion<\/h4>\n<p><strong>Design:<\/strong> Un studiu prospectiv, cvasi-experimental, de tip caz-control, \u00een care tratamentele de <strong>termoterapie oncologic\u0103<\/strong> (6-10 \u0219edin\u021be, cu o frecven\u021b\u0103 de 2-3 pe s\u0103pt\u0103m\u00e2n\u0103) au fost administrate \u00een asociere cu radioterapie standard (RT), chimioterapie (CT) sau o combina\u021bie a ambelor.<\/p>\n<p><strong>Dou\u0103 faze:<\/strong> Prima faz\u0103 de \u00eenv\u0103\u021bare (20 de pacien\u021bi). A doua faz\u0103 de tratament activ, cu 97 de pacien\u021bi \u00eenrola\u021bi, comparativ cu 196 de pacien\u021bi din grupul de control trata\u021bi cu radioterapie sau terapie cu interval QT f\u0103r\u0103 hipertermie \u00een 2012 \u00een ambele spitale (293 de pacien\u021bi \u00een total).<\/p>\n<\/div>\n<\/div>\n<div style=\"background: #0056b3; color: white; padding: 25px; border-radius: 12px; margin-bottom: 35px;\">\n<h4 style=\"margin-top: 0; text-align: center; text-transform: uppercase; letter-spacing: 1px;\">Cele 9 Situsuri Tumorale Tratate:<\/h4>\n<div style=\"display: grid; grid-template-columns: 1fr 1fr; gap: 15px; font-size: 15px;\">\n<ul style=\"margin: 0; padding-left: 20px;\">\n<li>Cervix, prostat\u0103, vezic\u0103 urinar\u0103<\/li>\n<li>Pancreas, cap \u0219i g\u00e2t inoperabile<\/li>\n<li>Tumori cerebrale, rect preoperator<\/li>\n<\/ul>\n<ul style=\"margin: 0; padding-left: 20px;\">\n<li>Tratament neoadjuvant inoperabil pentru cancerul de s\u00e2n avansat<\/li>\n<li>Cancer pulmonar f\u0103r\u0103 celule mici (NSCLC)<\/li>\n<li>Tratament paliativ \u00een diferite loca\u021bii<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<h3 style=\"color: #0056b3; border-bottom: 2px solid #0056b3; display: inline-block; padding-bottom: 5px; margin-bottom: 20px;\">Rezultate \u0219i Date Clinice Detaliate<\/h3>\n<div style=\"background: #fff; border: 1px solid #dee2e6; border-radius: 10px; padding: 25px; margin-bottom: 30px;\">\n<p><strong>Date preliminare de pe list\u0103:<\/strong> 22 de pacien\u021bi (9 la Spitalul Juan Roman Jimenez \u0219i 13 la Spitalul Carlos Haya).<\/p>\n<p><strong>Profil pacien\u021bi:<\/strong> Sex: 13 b\u0103rba\u021bi \u0219i 9 femei. V\u00e2rsta medie: 55 de ani (34-76 de ani).<\/p>\n<p><strong>Localizarea tumorii:<\/strong> glioblastom (2c), cap \u0219i g\u00e2t (7c), rect preoperator (3c), s\u00e2n (3c1), pl\u0103m\u00e2n (11c), prostat\u0103 (4c), col uterin (lc), metastaze osoase sacroiliace.<\/p>\n<p><strong>Protocol Tratament:<\/strong> <a href=\"https:\/\/andromedichyperthermia.com\/ro\/dispozitiv-hipertermie-locala-rf-mht\/\">Dispozitiv de <strong>hipertermie oncologic\u0103 avansata<\/strong>\u00a0HyDeep 600WM (Andromedic)<\/a> administrat \u00een 10 \u0219edin\u021be, de 2-3 ori pe s\u0103pt\u0103m\u00e2n\u0103, cu durata de 1 or\u0103, utiliz\u00e2nd \u00eentre 150W \u0219i 400W, \u00een func\u021bie de localizare, asociat tratamentului oncologic standard.<\/p>\n<\/div>\n<div style=\"background: #fff5f5; border-left: 5px solid #d9534f; padding: 20px; border-radius: 8px; margin-bottom: 35px;\">\n<h4 style=\"color: #a94442; margin-top: 0; font-weight: bold;\">Motive pentru \u00eentreruperea tratamentului:<\/h4>\n<ul style=\"margin-bottom: 0;\">\n<li><strong>Spitalul Juan R Jim\u00e9nez din Huelva:<\/strong> 3 cazuri, infec\u021bie \u00een loc de tratament (celulit\u0103 \u00een cancerul rectal), s\u00e2ngerare uterin\u0103 (cancer de col uterin) \u0219i \u00eentrerupere voluntar\u0103.<\/li>\n<li><strong>Spitalul C Haya de Malaga:<\/strong> 2 pacien\u021bi, 1 \u00een a 6-a \u0219edin\u021b\u0103, deoarece a tolerat bine tratamentul, \u0219i altul \u00een a 6-a \u0219edin\u021b\u0103, datorit\u0103 progresului bine tolerat.<\/li>\n<\/ul>\n<\/div>\n<div style=\"background: #eef9ff; border-left: 5px solid #31708f; padding: 20px; border-radius: 8px; margin-bottom: 35px;\">\n<h4 style=\"color: #31708f; margin-top: 0; font-weight: bold;\">Rezultate pacienti oncologici:<\/h4>\n<p><strong>19 pacienti de cancer sunt \u00een via\u021b\u0103<\/strong>, a\u0219teapt\u0103 evaluarea r\u0103spunsului, iar <strong>3 pacien\u021bi au decedat<\/strong> din cauza progresiei bolii (2 au primit chimioterapie exclusiv\u0103 \u0219i hipertermie HT, din cauza recidivei tumorale \u00een zona capului \u0219i g\u00e2tului iradiat\u0103 anterior, iar un alt pacient cu recidiv\u0103 tumoral\u0103 faringian\u0103 a primit RT paliativ\u0103 \u0219i HT).<\/p>\n<\/div>\n<div style=\"background: #d4edda; border: 1px solid #c3e6cb; padding: 30px; border-radius: 15px;\">\n<p style=\"font-size: 17px; color: #155724; margin-top: 0;\"><strong>Toleran\u021b\u0103: 81,2% dintre pacien\u021bii oncologici (18 p.) au indicat c\u0103 sunt mul\u021bumi\u021bi sau foarte mul\u021bumi\u021bi, iar 18,8% (4 p.) au indicat c\u0103 sunt &#8222;acceptabil&#8221;.<\/strong><\/p>\n<p style=\"font-size: 17px; color: #155724;\"><strong>Toxicitate: Toxicitate asem\u0103n\u0103toare arsurilor de gradul 1 a ap\u0103rut la 8 din 22 de pacien\u021bi (36,3%). Nu a ap\u0103rut toxicitate la 66,6%. Durere\/premix \u00een zona de tratament, gradul 1 (\u00een s\u00e2nul ulcerat), la un pacient de cancer.<\/strong><\/p>\n<hr style=\"border: 0; border-top: 1px solid #c3e6cb; margin: 20px 0;\" \/>\n<p style=\"font-style: italic;\">Experien\u021ba noastr\u0103 preliminar\u0103 sugereaz\u0103 fezabilitatea tratamentului de hipertermie oncologica \u00een cadrul spitalului public, \u00een cadrul \u00eengrijirilor de rutin\u0103, f\u0103r\u0103 a fi nevoie de resurse extraordinare \u0219i cu toleran\u021b\u0103 ridicat\u0103.<\/p>\n<p style=\"font-size: 19px; color: #155724; line-height: 1.5; margin-bottom: 0;\"><strong>CONCLUZII: Tratamentul de electro hipertermie RF modulata este fezabil \u0219i confortabil pentru 81,2% dintre pacien\u021bii oncologici din sistemul public de s\u0103n\u0103tate, cu toxicitate u\u0219oar\u0103 la 33% dintre pacien\u021bi atribuibil\u0103 tratamentului cu hipertermie. Selec\u021bia adecvat\u0103 a pacien\u021bilor de cancer este crucial\u0103.<\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Studiu de cvasi-fezabilitate: Termoterapie Oncologic\u0103 cu Hipertermie Local\u0103 Profund\u0103 HyDeep 600 WM \u0219i tratamente standard cancer Poster ESHO 2014: Validarea dispozitivului de hipertermie oncologic\u0103 Andromedic \u00een spitalele publice Studiu de cvasi-fezabilitate (caz-control) care asociaz\u0103 tratamentul cu hipertermie local\u0103 profund\u0103 HyDeep 600WM cu tratamente standard pentru cancer \u0219i descrie modelele de r\u0103spuns &nbsp; Introducere \u0219i Tehnologie&hellip;<\/p>\n","protected":false},"author":1,"featured_media":1948,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281,19],"tags":[166,1089,1090,165,1088],"class_list":["post-2934","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-studii-clinice","category-uncategorized-ro","tag-andromedic-hydeep-600wm","tag-dispozitiv-de-hipertermie-oncologica","tag-electro-hipertermie-rf-modulata","tag-hipertermie-locala-profunda","tag-studiu-clinic-esho"],"gutentor_comment":7,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/2934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/comments?post=2934"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/2934\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/media\/1948"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/media?parent=2934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/categories?post=2934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/tags?post=2934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}